Ridaura (auranofin) contains gold and, like other gold-containing drugs, can cause gold toxicity, signs of which include: fall in hemoglobin, leukopenia below 4,000 WBC/cu mm, granulocytes below 1,500/cu mm, decrease in platelets below 150,000/cu mm, proteinuria, hematuria, pruritus, rash, stomatitis or persistent diarrhea. Therefore, the results of recommended laboratory work (See PRECAUTIONS) should be reviewed before writing each Ridaura prescription. Like other gold preparations, Ridaura is only indicated for use in selected patients with active rheumatoid arthritis. Physicians planning to use Ridaura should be experienced with chrysotherapy and should thoroughly familiarize themselves with the toxicity and benefits of Ridaura.
In addition, the following precautions should be routinely employed:
- The possibility of adverse reactions should be explained to patients before starting therapy.
- Patients should be advised to report promptly any symptoms suggesting toxicity. (See PRECAUTIONS—Information for Patients.)
Ridaura (auranofin) is available in oral form as capsules containing 3 mg auranofin.
Ridaura (auranofin) is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. Ridaura should be added to a comprehensive baseline program, including non-drug therapies.
Unlike anti-inflammatory drugs, Ridaura does not produce an immediate response. Therapeutic effects may be seen after three to four months of treatment, although improvement has not been seen in some patients before six months.
When cartilage and bone damage has already occurred, gold cannot reverse structural damage to joints caused by previous disease. The greatest potential benefit occurs in patients with active synovitis, particularly in its early stage.
In controlled clinical trials comparing Ridaura with injectable gold, Ridaura was associated with fewer dropouts due to adverse reactions, while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect. Physicians should consider these findings when deciding on the use of Ridaura in patients who are candidates for chrysotherapy.
Media Articles Related to Ridaura (Auranofin)
Team publishes findings about compound with potential for treating rheumatoid arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2015.05.22]
Montana State University researchers and their collaborators have published their findings about a chemical compound that shows potential for treating rheumatoid arthritis.
Positive topline results announced from Phase 3 studies with sarilumab in patients with rheumatoid arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2015.05.21]
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that a Phase 3 study of sarilumab, an investigational, fully-human IL6 receptor antibody, met its co-primary efficacy endpoints of a...
Potential new drug target for the treatment of rheumatoid arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2015.05.21]
Researchers at the La Jolla Institute for Allergy and Immunology, in collaboration with colleagues the University of California, San Diego, identified a novel drug target for the treatment of...
Rheumatoid Arthritis (RA)
Source: MedicineNet Amyloidosis Specialty [2015.05.07]
Title: Rheumatoid Arthritis (RA)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 5/7/2015 12:00:00 AM
Weight loss may increase risk of premature death in patients with rheumatoid arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2015.05.06]
In contrast to the general population, low body mass index has been associated with premature death in patients with rheumatoid arthritis -- a situation known as the "obesity paradox.
Published Studies Related to Ridaura (Auranofin)
Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years. [1999.05]
BACKGROUND: Sulphasalazine (SSZ) has been reported to cause drug induced systemic lupus erythematosus (SLE), but diagnosis of this complication in the context of rheumatoid arthritis (RA) is difficult. OBJECTIVE: To determine prospectively: (1) if patients become seropositive for antinuclear antibodies (ANA) during prolonged treatment with SSZ without clinical evidence of SLE; (2) if ANA positive patients develop more adverse reactions than ANA negative patients; (3) if drug induced SLE was identified in this cohort... CONCLUSION: ANA positivity is common in patients with RA, but the presence or development of ANA did not increase the likelihood of withdrawing from treatment. No case of drug induced SLE was seen over five years in this study.
A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. [1998.09]
CONCLUSION: Despite the increased popularity of sulphasalazine and inmmunosuppressives, the drugs in this study continue to be used worldwide. The natural history of rheumatoid arthritis requires long-term follow up to establish drug efficacy. Evidence is needed as to whether the newer regimens will prove to be more effective and safer in the longer term than the commonly prescribed DMARDs. The data from this trial will provide a reference for comparison with future studies.
CPH-82 (Reumacon) versus auranofin (Ridaura): a 36-week study of their respective onset of action rates in RA. 
The onset of action rate of CPH-82 (Reumacon), was compared with that of auranofin (AUR; Ridaura) in a 36-week randomised, double-blind, multicentre study of 60 patients with rheumatoid arthritis (RA). As compared with respective baseline values, the CPH-82 group manifested significant improvement in grip strength, Ritchie's articular index (RAI), pain ratings, and HAQ (health assessment questionnaire) scores after 8, 12, 24, and 36 weeks of treatment, with the exception of the 24-week HAQ score...
Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. [1997.08]
The efficacy, toxicity and possible steroid-sparing properties of auranofin in the treatment of elderly-onset rheumatoid arthritis (EORA) were studied in a 2 yr prospective double-blind placebo-controlled clinical trial. Sixty-five patients with onset of arthritis after the age of 60 yr were randomized to either auranofin 3 mg b.i.d...
Sulfasalazine has a better efficacy/toxicity profile than auranofin--evidence from a 5 year prospective, randomized trial. [1996.11]
OBJECTIVE: To compare results of medium to longterm sulfasalazine and auranofin treatment in active rheumatoid arthritis (RA)... CONCLUSION: Sulfasalazine therapy was more likely to be continued for 5 years, suggesting better tolerability and/or efficacy than auranofin, and produced evidence of continuing benefit. Patients previously withdrawn from i.m. gold therapy because of inefficacy or minor toxicity should not be given auranofin therapy.
Clinical Trials Related to Ridaura (Auranofin)
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Recruiting]
This pilot clinical trial studies auranofin in treating patients with epithelial ovarian,
primary peritoneal, or fallopian tube cancer. Immunosuppressive therapy, such as auranofin,
may be an effective treatment for epithelial ovarian, primary peritoneal, or fallopian tube
Phase II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) [Recruiting]
The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat
patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or
prolymphocytic lymphoma (PLL).
Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection [Not yet recruiting]
The main purpose of the study is to evaluate the safety of oral auranofin, a gold compound,
in patients with HIV infection whose viral load has been suppressed by antiretroviral
therapy for no less than 3 years and have a CD4+ cell count over 500 cells/uL
Auranofin PK Following Oral Dose Administration [Recruiting]
Phase I, open-label study in 15 healthy adult subjects receive 6 mg of auranofin orally once
every 24 hours for 7days. Blood samples will be taken for 17 weeks following the last dose
of auranofin for determination of terminal phase pharmacokinetic parameters. Stool samples
will also be obtained for the measurement of gold.
Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome [Recruiting]
This randomized pilot clinical trial studies whether auranofin will relieve pain following
paclitaxel in patients who have previously experienced paclitaxel-induced pain. Auranofin is
a drug given by mouth to treat other diseases such as rheumatoid arthritis, and is being
studied to see if it will decrease pain following paclitaxel.
Page last updated: 2015-05-22